Synopsis of recent research by authors named "Tiepeng Li"
- Tiepeng Li's recent research focuses on the integration of immunotherapy and conventional cancer treatments, specifically exploring combination therapies such as low-dose anlotinib with immune checkpoint inhibitors for extensive-stage small cell lung cancer, aiming to enhance efficacy and safety for patients.
- Significant findings include the association of immune cell markers with cancer prognosis, such as the CD8 + PD-1 + to CD4 + PD-1 + ratio impacting outcomes in advanced melanoma, and the identification of microRNA as potential targets in aging and cancer therapy, indicating a growing emphasis on molecular markers in treatment response predictions.
- Li's work also addresses the complexities of cardiotoxic effects and cancer therapy-related complications, highlighting the need for innovative diagnostic and treatment strategies to mitigate cardiovascular risks associated with cancer therapies and improve patient outcomes in cancer care.
